Leading Brands

Brand building is at the core of our marketing strategy. A significant proportion of our revenues is derived from brands which are among top 10 in their respective subgroups. We derive a higher proportion of our revenues from our top 15 and top 25 mother brand groups, as compared to the average of the top 25 players in the IPM

  Top 15 Mother Brand Groups Revenue Contribution Top 25 Mother Brand Groups Revenue Contribution
Eris Lifesciences 75.22% 85.86%
Average of Top 25 Companies in IPM 50.27% 61.40%

Source: AIOCD MAT MARCH 2019

Top 15 Brands

Brand Year of launch Indication Subgroup(including combinations) Sales Value in INR Millions Brand CAGR (FY 14-19) Market CAGR (FY 14-19) Prescription rank
GLIMISAVE 2007 Anti – Diabetes Glimepiride 2,212 16% 15% 8
ERITEL 2008 Hypertension Telmisartan 1,235 16% 18% 9
OLMIN 2010 Hypertension Olmesartan 601 15% 13% 6
TENDIA 2015 Anti-Diabetes Teneligliptin 598 36.12% * 36.49% * 7
RENERVE 2003 Neuropathy Methylcobalamin and combinations 591 31% 7% 3
REMYLIN 2007 Diabetic Neuropathy Mecobalamin+Colecalciferol 556 9% 10% 2
RABONIK 2008 Gastroenterology Rabeprazole 553 5% 10% 15
TAYO 2011 Vit. D deficiency in Metabolic disorders Vitamin D 500 4% 14% 7
LNBLOC 2012 Hypertension Cilnidipine 494 46% 48% 2
CYBLEX 2014 Anti-Diabetes Gliclazide 396 72% 10% 6
ATORSAVE 2007 Lipid Lowering Atorvastatin 347 2% 7% 15
ROSIFLEX 2013 Anti-Arthritic Rosa Canina extract 326 49% 56% 3
CREVAST 2010 Lipid Lowering Rosuvastatin 303 11% 23% 12
RARICAP 1990 Iron supplement Conventional Iron 288 22% 5% 4
SERLIFT 1998 Antidepressant Sertraline 186 54% 14% 3

Source: AIOCD MAT MARCH 19 and SMSRC MAT FEBRUARY 2019
*Growth over FY 18 considered since brand launched post FY 14